Kazia Therapeutics (KZIA) Share-based Compensation (2009 - 2021)
Kazia Therapeutics (KZIA) posted Share-based Compensation of $466900.5 for Q4 2021, up 109.23% on a QoQ basis from $223154.4 in Q4 2020, and up 109.23% year-over-year from $223154.4 in Q4 2020.
Kazia Therapeutics (KZIA) Share-based Compensation (2009 - 2021) Analysis & Trends
Kazia Therapeutics' Share-based Compensation history runs 4 years deep, the most recent figure standing at $466900.5 for Q4 2021.
- Quarterly Share-based Compensation rose 109.23% year-over-year to $466900.5 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $2.0 million (down 3.79% YoY) and the FY2025 annual result came in at $418202.9, up 19.06% from the prior year.
- Share-based Compensation was $466900.5 for Q4 2021 at Kazia Therapeutics, up from $223154.4 in the prior quarter.
- Across five years, Share-based Compensation topped out at $466900.5 in Q4 2021 and bottomed at $223154.4 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Kazia Therapeutics | 4.11 Mn | 4.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 466,900.49 |
| Dec 31, 2021 | 466,900.49 |
| Dec 31, 2020 | 223,154.39 |
| Dec 31, 2020 | 223,154.39 |
| Dec 31, 2016 | 302,367.09 |
| Dec 31, 2016 | 302,367.09 |
| Dec 31, 2009 | 963,489.22 |
| Dec 31, 2009 | 963,489.22 |